Parexel Appoints Keri Mattox to Chief Business Officer: A New Era of Leadership Begins

Parexel, a leading global clinical research organization (CRO) known for its comprehensive Phase I to IV clinical development services, has announced the appointment of Keri Mattox as its first Chief Business Officer. In this newly established position, Mattox will oversee the company's business operations and growth initiatives. With over 25 years of experience in healthcare, she has expertise in corporate strategy, development, investor relations, communications, and environmental, social, and governance (ESG) programs. As a key member of the senior leadership team, Mattox will play a crucial role in steering Parexel's future growth, reporting directly to CEO Peyton Howell.

Before her tenure at Parexel, Keri Mattox was the Chief Communications and Administration Officer at Zimmer Biomet, a renowned global medical technology company. Earlier in her career, she led Integrated Corporate Communications on a global scale at W2O Group (now known as Real Chemistry) and worked as Vice President of Corporate and Investor Relations at AmerisourceBergen, a Fortune 20 enterprise now called Cencora. Additionally, Mattox has held senior leadership roles at Endo International and Auxilium Pharmaceuticals.

Ms. Mattox mentioned, “I’m extremely excited to join Parexel at such a pivotal time in the company’s evolution and growth. Parexel has demonstrated operational excellence and a truly Patients-First approach, providing the world’s leading biopharmaceutical companies with integrated solutions and expertise that accelerate new therapies to market. I look forward to working with the team as we continue to expand our global footprint, drive above-market growth in key segments and achieve new innovation milestones — all with the goal of delivering better trials for patients, faster.”

Peyton Howell, Chief Executive Officer, said in a statement, “We’re pleased to welcome Keri to Parexel during an important time in our strategic transformation. Her extensive expertise, proven leadership and strong partnerships in the pharmaceutical and medical technology industries will be extremely valuable as we position Parexel for the next phase of our growth. I know she will be a tremendous asset to the company and our leadership team.”